Haloperidol is one of the most widely used antipsychotic medications in the world, prescribed primarily for schizophrenia, acute psychotic episodes, and severe agitation. First synthesized in 1958, it belongs to the butyrophenone class of drugs and works by blocking dopamine receptors in the brain. But its reach extends well beyond psychiatry: haloperidol shows up in intensive care units for delirium, in emergency departments for intractable vomiting, in neurology clinics for tic disorders, and even as a rescue treatment for migraine. That breadth of application, combined with a side-effect profile that demands respect, makes it a drug worth understanding in detail.
Schizophrenia and Acute Psychosis
Haloperidol’s original and best-established role is treating schizophrenia and other psychotic disorders. A Cochrane systematic review describes it as highly effective against the “positive symptoms” of schizophrenia, including hallucinations, delusions, and disorganized thinking.1PubMed Central. Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders For decades it has been among the most commonly prescribed antipsychotics for acute episodes.2PubMed. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia
One reason clinicians have stuck with haloperidol is that its dose-response relationship is well characterized. Research on blood levels shows that the drug’s clinical effect follows a pattern: benefits increase at low concentrations, peak at a moderate level, and can actually decline at very high concentrations. Patients whose blood levels fall within that optimal range respond significantly better than those whose levels are too low or too high.3PubMed. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia This means dosing is not simply “more is better,” and monitoring blood levels can help fine-tune treatment, especially in patients who are not responding as expected.
Haloperidol does not do much for the “negative” symptoms of schizophrenia, such as social withdrawal, flat emotional expression, and lack of motivation. That limitation is shared with most first-generation antipsychotics and is one of the reasons newer drugs have been developed.
Calming Acute Agitation in Emergencies
When someone in an emergency department or psychiatric ward becomes severely agitated or aggressive, haloperidol is one of the go-to medications for what clinicians call “rapid tranquilization.” It is effective given by injection when a person cannot or will not take oral medication, and it acts relatively quickly.
Used alone, haloperidol calms agitation but carries a meaningful risk of movement-related side effects like muscle stiffness and involuntary spasms. That is why it is frequently combined with another medication. A review of the evidence found that combining haloperidol with the antihistamine promethazine may be the strongest option: promethazine adds sedation while its anticholinergic properties reduce the risk of the muscle-related side effects haloperidol can cause.4PubMed Central. Treatment Options for Acute Agitation in Psychiatric Patients: Theoretical and Empirical Evidence Haloperidol combined with a benzodiazepine like lorazepam is another well-supported option.5PubMed Central. The Use of Rapid Tranquilization in Aggressive Behavior In practice, the choice often depends on the clinical setting and the suspected cause of the agitation.
Delirium in Hospitalized Patients
Delirium is a sudden state of confusion that commonly affects patients in intensive care units, especially older adults and those on mechanical ventilators. Haloperidol has been used for decades to manage agitation and hallucinations associated with delirium, and many hospital protocols still include it as a first-line option.
The evidence behind that practice, however, is thinner than many clinicians assume. A large trial published in the New England Journal of Medicine noted that while haloperidol is frequently used for ICU delirium, solid proof of its effectiveness remains limited.6PubMed. Haloperidol for the Treatment of Delirium in ICU Patients The drug may ease the visible symptoms of agitation without necessarily shortening the delirium itself or improving outcomes like time on a ventilator or length of hospital stay. This is an area where practice has run ahead of the evidence, and guidelines have grown more cautious in recent years.
Tic Disorders and Tourette Syndrome
Haloperidol was one of the first medications shown to reduce tics in people with Tourette syndrome and other tic disorders, and it remains an option when tics are severe enough to interfere with daily life. In a study comparing haloperidol to the newer antipsychotic aripiprazole in children with tic disorders, both drugs reduced motor and vocal tics significantly, with haloperidol cutting motor tic scores by about 59% and vocal tic scores by about 66%.7PubMed Central. Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders There was no significant difference in effectiveness between the two drugs.
Despite that efficacy, haloperidol has largely fallen out of favor as a first-choice tic medication because its side effects, particularly sedation and movement-related problems, tend to be harder on patients than the side effects of newer alternatives. Most specialists today try other options first and reserve haloperidol for cases that do not respond.
Nausea and Vomiting
Haloperidol has antiemetic properties, meaning it can suppress nausea and vomiting. This makes it useful in two distinct settings.
In palliative care, it is sometimes given to patients with advanced cancer who experience persistent nausea. A Cochrane review looked at the evidence for this use and found it incomplete: one trial suggested haloperidol was effective for roughly two-thirds of cancer patients with nausea, but the full results had not been published at the time of review.8PubMed Central. Haloperidol for the treatment of nausea and vomiting in palliative care patients Despite the limited formal evidence, many palliative care clinicians use it based on clinical experience, often at low doses.
The more surprising antiemetic application is for cannabinoid hyperemesis syndrome, a condition of relentless vomiting that can occur in people who use cannabis heavily over long periods. Standard anti-nausea drugs often fail to control these episodes, but haloperidol has shown promise. Case reports have described it as a successful rescue treatment for the unrelenting symptoms.9PubMed Central. Is haloperidol the wonder drug for cannabinoid hyperemesis syndrome? A randomized trial comparing intravenous haloperidol to ondansetron (the standard anti-nausea drug) for cannabis hyperemesis syndrome was conducted to test this observation more rigorously.10PubMed. Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial This is an area where emergency physicians have increasingly turned to haloperidol when traditional antiemetics fall short.
Off-Label Migraine Treatment
Haloperidol has found a niche as a rescue medication for acute migraine, particularly when standard treatments have already been tried and failed. A randomized, double-blind, placebo-controlled study found intravenous haloperidol to be very effective at relieving migraine-associated pain. Because most patients in the study had already taken other medications without relief, the researchers concluded that haloperidol works as an effective rescue even after other treatments fail.11PubMed. Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study
This is not a mainstream migraine therapy. You are unlikely to receive it at your first visit for a headache. But for patients stuck in a prolonged, treatment-resistant migraine episode in an emergency department, it represents one more tool in the cabinet.
Long-Acting Injectable Form
One of the persistent challenges in treating schizophrenia is medication adherence. Many patients stop taking daily oral pills, which leads to relapse. To address this, haloperidol is available as haloperidol decanoate, a long-acting injection given into muscle tissue that slowly releases the drug over weeks.12PubMed Central. Depot haloperidol decanoate for schizophrenia Developed in the 1960s, depot injections of this type became a standard strategy for long-term maintenance treatment. A patient receiving haloperidol decanoate typically gets an injection every four weeks, eliminating the need to remember daily doses.
The trade-off is that if side effects develop, you cannot simply stop taking a pill. The drug remains in the body for weeks after each injection, so side effects may persist until the drug clears. This makes careful dose selection upfront more important than with the oral form.
How It Works in the Brain
Haloperidol’s therapeutic effects stem from its ability to block dopamine D2 receptors, particularly in a brain region called the striatum. By occupying these receptors, it dampens the overactive dopamine signaling thought to drive psychotic symptoms like hallucinations and delusions.
The pharmacology, though, is not as clean as “block dopamine, stop psychosis.” Research using proteomic analysis in mice has shown that chronic haloperidol treatment alters more than 400 proteins in the striatum, many of them involved in signaling between neurons. Electrophysiological recordings reveal that haloperidol does reduce the excitability of the D2-receptor neurons it targets, but it also affects neighboring D1-receptor neurons by shifting the balance of inhibitory and excitatory signaling they receive.13Nature. Chronic treatment with D2-antagonist haloperidol leads to inhibitory/excitatory imbalance in striatal D1-neurons These broader effects on brain circuitry help explain both haloperidol’s therapeutic power and its capacity for causing movement-related side effects.
Movement-Related Side Effects
The side effects that most define haloperidol’s reputation are extrapyramidal symptoms: a family of movement problems caused by disruption of the brain’s motor control circuits. These include muscle stiffness, tremor, restlessness (akathisia), and involuntary muscle contractions (dystonia). Dystonia can be dramatic, causing a person’s neck to twist, their jaw to lock, or their eyes to roll upward. It is the most intrusive and disabling of these effects, and its likelihood tracks closely with how strongly a drug blocks D2 receptors. Haloperidol, as a potent D2 blocker, carries a higher risk than many alternatives.14PubMed Central. Neurobiological mechanisms associated with antipsychotic drug-induced dystonia
A comparison of haloperidol to second-generation antipsychotics for long-term schizophrenia treatment confirmed that extrapyramidal side effects were significantly more common in the haloperidol group than in patients taking olanzapine.15PubMed. Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia The olanzapine group, on the other hand, experienced more weight gain. That trade-off, movement problems versus metabolic problems, is a recurring theme when comparing older and newer antipsychotics.
Tardive Dyskinesia
Tardive dyskinesia is a separate and more concerning movement disorder that can develop after months or years of antipsychotic use. It involves involuntary, repetitive movements, often of the face: lip smacking, tongue protrusion, jaw movements, and grimacing. Unlike the acute movement side effects that appear early and often resolve when the drug is stopped, tardive dyskinesia can be permanent.
Adults treated with haloperidol face an annual risk of tardive dyskinesia of about 5.4%. In a head-to-head comparison, roughly 4.6% of patients receiving haloperidol met criteria for tardive dyskinesia over about seven months of treatment, compared to 1% in the olanzapine group.16Med Case Rep Rev. Tardive dyskinesia: Risk factors, prevention, and treatment These numbers help explain why clinicians are cautious about long-term haloperidol use and often prefer alternatives for maintenance therapy when available.
Heart Rhythm Concerns
Haloperidol can prolong the QT interval on an electrocardiogram, a change in the heart’s electrical cycle that, in rare cases, triggers a dangerous heart rhythm called torsades de pointes. This risk is most pronounced when the drug is given intravenously. A review of reports to the FDA identified 70 cases of QT prolongation or torsades de pointes associated with IV haloperidol, including three sudden cardiac arrests. In cases where the QT interval was measured after the event, it was prolonged beyond 450 milliseconds in 96% of patients.17PubMed. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?
Among antipsychotics, intravenous haloperidol carries an elevated risk for this complication, though some older antipsychotics like thioridazine are even more strongly associated with QT prolongation.18PubMed. QTc prolongation, torsades de pointes, and psychotropic medications Documented cases have shown QT intervals returning to normal and the dangerous rhythm stopping once haloperidol was discontinued.19PubMed. Haloperidol-induced torsades de pointes Because of this risk, many hospitals now require heart monitoring for patients receiving IV haloperidol, and the FDA has issued extended warnings about it.
Neuroleptic Malignant Syndrome
Neuroleptic malignant syndrome is a rare but life-threatening reaction to antipsychotic medications. It involves high fever, severe muscle rigidity, altered consciousness, and instability in blood pressure and heart rate. It can develop unpredictably, sometimes after a single dose and sometimes after years of uneventful use. Haloperidol, as one of the most potent D2 blockers, is frequently the drug implicated in case reports.
In one published case, a patient developed a fever of 106°F, mental status changes, and muscle rigidity after receiving parenteral haloperidol.20TAJ: Journal of Teachers Association. Neuroleptic Malignant Syndrome Associated with Haloperidol In another, a patient who received multiple doses of haloperidol while also taking the antidepressant paroxetine was transferred to the ICU after developing the syndrome; all antipsychotic and serotonergic medications were stopped once the diagnosis was made.21PubMed Central. Haloperidol-Induced Neuroleptic Malignant Syndrome: A Case Report The key to managing this condition is recognizing it quickly and immediately stopping the offending drug.
The Dementia Warning
All antipsychotics carry an FDA black-box warning against use in elderly patients with dementia-related psychosis, citing an increased risk of death. But the risk is not the same across all drugs. A large study comparing individual antipsychotics in dementia patients found that haloperidol was associated with the highest mortality risk, about 54% higher than risperidone (the reference drug). Quetiapine carried the lowest risk in the group. The increased mortality with haloperidol was most concentrated in the first 30 days of treatment and dropped sharply after that.22PubMed Central. Risk of mortality among individual antipsychotics in patients with dementia
This finding has practical implications. When an antipsychotic is genuinely needed for dangerous agitation or psychosis in an elderly person with dementia, the data suggest haloperidol should not be the first choice. Quetiapine or olanzapine, despite their own risks, have more favorable mortality profiles in this population.
Why Your Genetics Affect How You Process It
Haloperidol is broken down in the liver primarily by two enzyme systems, CYP2D6 and CYP3A4, and the speed at which your body metabolizes it varies considerably depending on your genetic makeup.23PubMed. Pharmacokinetics of haloperidol: an update Roughly 5 to 10 percent of people of European descent are “poor metabolizers” through the CYP2D6 pathway, meaning the enzyme works slowly or barely at all. In those individuals, haloperidol blood levels can climb significantly higher on the same dose: one study found that predicted poor metabolizers had drug concentrations about 86% higher than normal metabolizers on equivalent doses.24PubMed. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients
When someone is a poor CYP2D6 metabolizer, the body relies more heavily on the CYP3A4 pathway to clear haloperidol. This creates a vulnerability: if that backup pathway is then blocked by another medication, drug levels can spike dangerously. A case report described exactly this scenario, where a patient who was a CYP2D6 poor metabolizer developed severe extrapyramidal symptoms only after the antibiotic ciprofloxacin (a CYP3A4 inhibitor) was added to their regimen.25Pharmacogenomics. CYP2D6 *6/*6 genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms Pharmacogenomic testing is not yet routine before prescribing haloperidol, but cases like this illustrate why it could help prevent serious adverse reactions.
What Happens When You Stop Taking It
Stopping haloperidol after long-term use is not as simple as just dropping the pills. Chronic use causes the brain to adapt to the constant D2 receptor blockade by increasing the number and sensitivity of those receptors. When the drug is removed, this “supersensitivity” can lead to a rebound: receptors that were being suppressed suddenly become overactive. At the same time, withdrawal from haloperidol has been linked to increased cholinergic activity, which can cause symptoms like depression of motor activity and lowered seizure thresholds.26Pro Research Analysis. Haloperidol Withdrawal Symptoms: An Overview
For this reason, psychiatrists generally taper haloperidol gradually rather than stopping it abruptly. The tapering schedule depends on how long the patient has been on the drug and how high the dose is. Patients who have been on high doses for years need slower, more careful reduction. Even with gradual tapering, some people experience temporary worsening of symptoms before stabilizing.
A Drug Discovered in the Late 1950s That Still Gets Used Daily
Haloperidol was synthesized on February 11, 1958, and its discovery is considered one of the major advances of twentieth-century psychiatry.27PubMed. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice Its name comes from the two halogen atoms in its molecular structure. Beyond its direct clinical impact, haloperidol played a foundational role in biological psychiatry: it enabled the development of animal models for predicting antipsychotic effects and helped establish the dopamine hypothesis of schizophrenia, the idea that overactive dopamine signaling is central to the disease.
More than six decades later, haloperidol remains on the World Health Organization’s List of Essential Medicines. In many low- and middle-income countries, it is the only antipsychotic reliably available and affordable. Even in wealthy healthcare systems where newer drugs have largely replaced it for long-term use, haloperidol holds its ground in acute settings: emergency rooms, operating suites, and intensive care units, where its predictable onset, injectable formulations, and decades of clinical familiarity keep it in regular rotation. The newer antipsychotics may have gentler side-effect profiles for chronic treatment, but few drugs match haloperidol’s versatility when a rapid, reliable effect is needed right now.